Adagrasib Shows Durable Benefit in KRAS-Mutated NSCLC Adagrasib Shows Durable Benefit in KRAS-Mutated NSCLC

Adagrasib shows durable clinical benefit in previously treated, advanced KRASG12C-mutated non-small cell lung cancer, including patients with brain metastases.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news